Alternative splicing is a major diversification mechanism in the human transcriptome and proteome. Several diseases, including cancers, have been associated with dysregulation of alternative splicing. Thus, correcting alternative splicing may restore normal cell physiology in patients with these diseases. This paper summarizes several alternative splicing-related diseases, including cancers and their target genes. Since new cancer drugs often target spliceosomes, several clinical drugs and natural products or their synthesized derivatives were analyzed to determine their effects on alternative splicing. Other agents known to have modulating effects on alternative splicing during therapeutic treatment of cancer are also discussed. Several commonly used bioinformatics resources are also summarized.
1. Introduction to Alternative Splicing
Alternative splicing of RNA is a key mechanism of increasing complexity in mRNA and proteins [1]. Since alternative splicing apparently controls almost all human gene activities, imbalances in the this splicing process may affect the progression of various human diseases and cancers [2]. Varying alternations in excision and/or inclusion of exons may generate different mRNA transcripts and corresponding proteins. Therefore, in addition to mediating changes in protein structure, function, and localization [3], alternative splicing in higher eukaryotes affects the differentiation and development of cancer and other diseases [4].
2. Alternative Splicing and Diseases
Alternative RNA splicing is commonly reported in neurological and muscle diseases [5–7]. Studies show that these diseases at least partly result from alternative splicing, which regulates the complexity of integral membrane proteins, including changes in their topology, solubility, and signal peptides [3]. For example, aberrant alternative splicing has shown associations with Parkinson disease [3, 8]. For spinal muscular atrophy (SMA), the level of survival motor neuron (SMN) protein was downregulated by its alternative splicing [9]. Therapies for SMA have recently improved by targeting RNA splicing for inclusion of exon 7 into SMN mRNA [10]. Phorbol 12-myristate 13-acetate was reported to modulate the alternative splicing of sarcoplasmic reticulum Ca2+-ATPase1 (SERCA1) which is dysregulated in myotonic dystrophy type 1 disease [11].
Additionally, alternative splicing reportedly regulates heart development [12], cardiovascular disease [13], blood coagulation [14], cholesterol homeostasis [15], cellular proliferation, apoptosis, immunity [16], and systemic sclerosis [17]. For example, heart-specific knockout of the serine/arginine- (SR-) rich family of splicing factors, ASF/SF2, produces cardiomyopathy and affects splicing of cardiac troponin T and LIM domain-binding protein [18]. Specific CLK inhibitors (dichloroindolyl enaminonitrile KH-CB19) of CDC2-like kinase isoforms 1 and 4 (CLK1/CLK4) can inhibit phosphorylation of cellular SR splicing factors and affect the splicing of tissue factor isoforms flTF (full-length TF) and asHTF (alternatively spliced human TF) [19].
Using exon array, the global mRNA splicing profile of ischemic cardiomyopathy has been investigated, and the alternative splicing of four main sarcomere genes, such as cardiac troponin T (TNNT2), cardiac troponin I (TNNI3), myosin heavy chain 7 (MYH7), and filamin C, gamma (FLNC), was dysregulated [20]. The alternative splicing of blood coagulation-related genes including tissue factor (coagulation factor III), tissue factor pathway inhibitor (TFPI), and coagulation factor XI has been well reviewed [14]. For cholesterol production and uptake, alternative splicing of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) and LDL receptor (LDLR) can suppress their protein activities [21, 22]. Proprotein convertase subtilisin/kexin type 9 (PCSK9) [23], HMG-CoA synthase (HMGCS1) [24], and mevalonate kinase [25] also reported to be involved in cholesterol biosynthesis and receptor-mediated uptake through alternative splicing.
3. Alternative Splicing and Cancer
In cancer-associated genes, splicing has important roles in oncogenesis, tumor suppression [26], and metastasis [27]. Alterations in alternative splicing are commonly reported in various cancers [27–29]. Reported examples include p53 and PTEN [30], kallikrein-related peptidase 12 (KLK12) [31], breast cancer early-onset 1 (BRCA1) [32], protein N-arginine methyltransferases 2 (PRMT2) [33], and CDC25 phosphatases [34] in breast cancer; lysyl oxidase-like 4 (LOXL4) [35] and growth factor receptor-bound protein 7 (GRB7) in ovarian cancer [36]; androgen receptor in prostate cancer [37]; tissue inhibitor of metalloproteinases-1 (TIMP1) and the cell adhesion molecule CD44 in colon cancer [38, 39]; Bcl-xL, CD44, and others in lung cancer [40]; calpain 3 in melanoma [41]; and Krüppel-like factor 6 (KLF6) in liver cancer [42]. Therefore, alternative spliced variants are potential biomarkers [43, 44] for the cancer diagnosis/prognosis and may be the targets for cancer therapy based on specific splicing correction treatments.
Single nucleotide polymorphisms (SNPs) affecting exon skipping has reviewed to confer to complex diseases [45]. The improvement of high-throughput technologies such as RNA-Seq [46, 47] and exon arrays [48, 49] is helpful to identify the genome-wide cancer-associated splicing variants. Splicing changes may associate with lung and prostate cancer risk in terms of some SNPs. For example, a coding synonymous SNP G870A of cyclin D1 (CCND1) with a modulating ability to its splice pattern was reported to be associated with lung cancer susceptibility [50]. Similarly, some coding synonymous SNPs may generate new splicing sites in the middle of an exon of p53 gene to change splicing [51]. Mutations in the adenomatous polyposis coli (APC) [52] and BRCA1 [53, 54] genes have reported to skip exon by altering splicing. Furthermore, an intronic SNP, IVS −27 G>A/IVSΔA, creates a new splicing factor SR-binding site and deletes two other overlapping SR-binding sites, generating three alternative splicing forms of KLF6 (KLF6 SV1-3) [55]. This SNP was found to be associated with prostate cancer [56]. For lung cancer study, the tumor patients with overexpression of KLF6 SV1 have lower survival [56, 57].
Actually, the information of many SNPs located in 3′ and 5′ splicing sites is searchable in the dbSNP in NCBI website (http://www.ncbi.nlm.nih.gov/snp) when the “limit” function is chosen. Researchers may choose the SNPs of splicing sites located in interested genes to identify their association relationships to diseases and cancers. A database consisting of genome-wide SNP and splicing sites, namely, ssSNPTarget [58] was designed to search the splice site SNPs (ssSNPs) by input of gene symbol, SNP rs number, transcript ID, or genomic position (http://variome.kobic.re.kr/ssSNPTarget/).
4. Alternative Splicing-Related Drugs and Natural Products
Splice modulating therapies have been developed for human disease [59–61] and cancer therapy [62, 63]. Antitumor drugs have been developed to target alternative splicing [64], splice variants [65], and spliceosomes [66, 67]. For example, pharmacological interventions may be affected by mRNA transcript diversity [68]. To correct aberrant splicing, specific mRNA transcripts have been targeted in genetic disorders such as Duchenne muscular dystrophy. Since mutations of splicing factor 3B subunit 1 (SF3B1) are common in several haematological malignancies, the use of various natural products and their synthetic derivatives in therapies targeting SF3B has proven highly effective [67].
For drug discovery for SMA, several small molecules including sodium vanadate [69], aclarubicin [70], and indoprofen [71], hydroxyurea [72], valproate [73], 5-(N-ethyl-N-isopropyl)-amiloride (EIPA) [74], and phenylbutyrate [75] that increases inclusion of exon 7 of SMN2 gene have been identified, although some of them may have side effects. Recently, novel phosphatase modulators, namely, pseudocantharidins have been discovered with the similar regulating function to SMN splicing [76]. Valproic acid was found to enhance SMN2 expression in SMA cell model involving the SF2/ASF and hnRNPA1 [77].
Clinical drugs such as novantrone (mitoxantrone) can enhance the effectiveness of therapeutic treatments for familial neurodegenerative diseases by stabilizing the tau pre-mRNA splicing regulatory element [78]. Tamoxifen has proven effective for clinical treatment of estrogen receptor- (ER-) positive breast cancer [79]. In endometrial cancer cells, alternative splicing of ER involving ER-alpha36 is also known to enhance the agonist activity of tamoxifen [80].
Natural products, including many xenobiotics, are also known to impair alternative splicing [81]. For example, natural products such as pladienolide B and FR901464 [82, 83] are known to affect spliceosome function. However, the synthesis of these compounds is complicated by their multiple stereocenters. A recent study synthesized Sudemycins, which are novel analogues of FR901464. By inducing alternative gene splicing, the Sudemycins conferred both in vitro and in vivo antitumor effects [84]. Alternative splicing has also shown regulating effects on the antitumor drug Spliceostatin A, a stabilized derivative of a Pseudomonas bacterial fermentation product [85] which specifically targets the SF3b spliceosome subcomplex to inhibit pre-mRNA splicing [86]. Meayamycin, an analogue of the natural antitumor product FR901464 [87], inhibits RNA splicing against multidrug-resistant cells and performs antiproliferative effect against human breast cancer MCF-7 cells by suppression of alternative splicing [88]. These results suggest that, because of their modulating effects on RNA splicing, xenobiotic analogs have potential use as chemical probes and as anticancer agents. Similarly, the polyketide natural product borrelidin inhibits cancer metastasis by modulating alternative splicing in VEGF [89]. Antitumor effects involving alternative splicing [90, 91] have also been reported in natural dietary products. For example, resveratrol can modulate exon inclusion of SRp20 and SMN2 pre-mRNAs and induce the expression of processing factors of alternative splicing such as ASF/SF2, hnRNPA1, and HuR [92].
Recent studies have investigated the role of splice variants in apoptotic pathways [93, 94]. Regulation of alternative splicing genes may have anticancer effects. For example, BCL-Xs and BCL-XL have been associated with proapoptotic and antiapoptotic effects, respectively, during the progression of cancer [67, 95, 96]. The ratio of BCL-Xs/BCL-XL can be decreased by the treatment of protein kinase C (PKC) inhibitor and apoptotic inducer staurosporine in 293 cells [97]. Soluble and membrane-bound forms of TNF receptor superfamily, member 6 (FAS) containing exons 5/7 and 5/6/7 also display proapoptotic and antiapoptotic effects, respectively [67]. The caspase 9 (CASP9) gene has two antagonistic isoforms, proapoptotic Casp9a and prosurvival Casp9b, and its splicing is dysregulated in NSCLC lung cancer cell lines [98].
Alternative splicing is regulated by chromatin structure and histone modifications [4]. In thyroid tumor cells, for example, histone deacetylase inhibitors such as butyrate modulate transcription and alternative splicing of prohibitin [99]. A study of bovine epithelial cells showed that butyrate, a major metabolite generated by bacterial fermentation of dietary fiber in colon cells, has regulating effects on apoptosis and cell proliferation through alternative splicing [100]. Since histone deacetylase inhibitor may have antitumor effects, the identification of this kind of inhibitor in natural products can improve drug development for tumor therapy.
5. Alternative Splicing-Related Bioinformatics Resources
Several bioinformatics analyses for the detection and regulation of alternative splicing have been well reviewed [101–103]. However, these literatures mainly focused on the methodology for detection of alternative splicing, and the databases of alternative splicing are less addressed and summarized. Here, we collect several helpful bioinformatics resources related to alternative splicing as shown in Table 1.
The bioinformatics resources related to alternative splicing (yrs 2001–2013)*.
AsMamDB [104]
An alternative splice database of mammals (website is unavailable)
PALS db [105]
Putative alternative splicing database
ASAP [106]
Alternative splicing annotation project (http://www.bioinformatics.ucla.edu/ASAP/)
EASED [107]
Extended alternatively spliced EST database
AVATAR [108]
Database for EST and mRNA
MAASE [109]
Alternative splicing database designed for splicing microarray (http://maase.genomics.purdue.edu/)
PolyA_DB [110]
Database for mRNA polyadenylation in mammalian
AltTrans [111]
Annotation for both alternative splicing and alternative polyadenylation
GRSDB [112]
Database of quadruplex forming G-rich sequences in alternative splicing sequences (http://bioinformatics.ramapo.edu/grsdb/)
HOLLYWOOD [113]
A comparative relational database of alternative splicing (http://hollywood.mit.edu/)
ASD [114]
A bioinformatics resource on alternative splicing
Splicy [115]
Prediction of alternative splicing from Affymetrix data
ASTALAVISTA [116]
Analysis of alternative splicing for custom datasets (http://genome.imim.es/astalavista/)
BIPASS [117]
Bioinformatics pipeline alternative splicing services
ECgene [118]
Alternative splicing database update (http://genome.ewha.ac.kr/ECgene/)
EuSplice [119]
A resource for splice signals and alternative splicing in eukaryotic genes (http://www.genome.com/products-1/integrated-genomics-resources/eusplice)
SpliceCenter [120]
A server for analysis of alternative splicing on RT-PCR, RNAi, microarray, and peptide-based studies (http://discover.nci.nih.gov/splicecenter/)
ASPicDB [121]
Database for alternative splicing analysis (http://www.caspur.it/ASPicDB/)
The alternative splicing mutation database [122]
A hub for analyzing alternative splicing from mutational evidence
ProSAS [123]
Database for analyzing alternative splicing in the context of protein structures (http://www.bio.ifi.lmu.de/ProSAS/)
Splice-mediated Variants of Proteins (SpliVaP) [124]
Signatures for protein isoforms due to alternative splicing (http://www.bioinformatica.crs4.org/tools/dbs/splivap/)
AspAlt [125]
A interdatabase for comparative analysis of alternative transcription and splicing (http://www.genome.com/products-1/integrated-genomics-resources/products-integrated-genomics-resources-igr-aspalt)
ASTD [126]
Alternative splicing and transcript diversity database
TassDB2 [127]
A comprehensive database of subtle alternative splicing (http://www.tassdb.info/)
H-DBAS [128]
Human-transcriptome database for alternative splicing (http://h-invitational.jp/h-dbas/)
SPLOOCE [129]
Analysis server of human splicing variants (http://www.bioinformatics-brazil.org/splooce/)
APPRIS [130]
Annotation of human alternative splice isoforms (http://appris.bioinfo.cnio.es/)
SpliceAid 2 [131]
Database of human splicing factors expression data and RNA target motifs (http://www.introni.it/spliceaid.html)
TFClass [132]
Classification of human transcription factors (http://tfclass.bioinf.med.uni-goettingen.de/)
*The websites for some resources without function currently are not provided.
For example, AsMamDB [104] is one of the early established alternative splice databases of mammals, although their websites are not functional currently. PALS db [105] provides the putative alternative splicing database based on UniGene clusters of human and mouse sources which mainly consist of EST data. Similarly, some databases such as EASED [107] and AVATAR [108] are constructed by datasets of EST and mRNAs. ASAP [106] provides the detail annotation for exon-intron boundary, alternative splicing, and its tissue specificity for the user to design probes for distinguishing different splicing isoforms. MAASE [109] is also specifically designed to apply in splicing microarray experiments. In contrast, Splicy [115] provide the web-based tool to predict possible alternative splicing events from Affymetrix probe set inputs. ASTALAVISTA [116] provides alternative splicing prediction for transcriptome data from GENCODE, REFSEQ, and ENSEMBL as well as from custom gene datasets. Furthermore, SpliceCenter [120] is a web server for predicting the influence of alternative splicing on RT-PCR, RNAi, microarray, and peptide-based data.
Both PolyA_DB [110] and AltTrans provide the information for alternative polyadenylation [111]. For AltTrans, the AltSplice pipeline on splicing and the AltPAS pipeline on polyadenylation were implemented. ASTD [126] also provides the variants for splicing, transcription initiation, and polyadenylation. Of note, the dataset of transcriptomics for alternative splicing is larger than for alternative polyadenylation. GRSDB [112] is a mammalian database of alternative splicing based on quadruplex forming G-rich sequences which modulate the 3′ end processing of pre-mRNAs.
Additionally, several comprehensive databases for alternative splicing have been developed such as HOLLYWOOD [113], ASD [114], BIPASS [117], ECgene [118], ASPicDB [121], AspAlt [125], H-DBAS [128], SPLOOCE [129], and APPRIS [130]. For example, the ECgene provides EST and serial analysis of gene expression (SAGE) data-based annotation and visualization for alternative splicing (AS). The ASPicDB provides EST-based tissue-specific splicing information of normal and cancer cells. The H-DBAS provides alternative splicing annotation based on RNA-Seq transcriptomics data. The APPRIS provides the annotation for principal isoform as the standard reference sequence for each gene.
Some resources of alternative splicing have special features such as splice signals in EuSplice [119], tandem splice sites in TassDB2 [127], mutational evidence-based analysis in Alternative Splicing Mutation Database [122], splicing proteins in SpliceAid 2 [131], and transcription factors in TFClass [132]. However, the impacts of alternative splicing on the spliced transcripts encoded protein structure are less addressed. Some databases such as ProSAS [123] and SpliVaP [124] also provide the protein isoforms from the alternative splicing effects. In ProSAS, the protein isoforms of splicing transcripts are annotated in Ensembl or SwissProt. In SpliVap, protein signatures of alternative forms are annotated in terms of Pfam domains and PRINTS fingerprints.
6. Conclusion
Accumulating evidence shows that alternative splicing can be selectively targeted in several genes of cancer cells. An exciting possibility raised by this study is that the effectiveness of anticancer therapies may be enhanced by clinical drugs, natural products, and their synthesized analogs that target alternative splicing machinery. Some alternative splicing-related databases and web servers may also helpful to improve the alternative splicing therapy for treating cancer and other diseases.
Acknowledgments
This study was supported by Grants from the National Science Council (NSC101-2320-B-037-049), the Department of Health, Executive Yuan, China (DOH102-TD-C-111-002), the Technology Development Programs, Ministry of Economic Affairs, Taiwan (102-EC-17-A-01-04-0525), the Kaohsiung Medical University Research Foundation (KMUER001), and the National Sun Yat-Sen University-KMU Joint Research Project (no. NSYSU-KMU 102-034).
BrettD.PospisilH.ValcárcelJ.ReichJ.BorkP.Alternative splicing and genome complexity200230129302-s2.0-003633812710.1038/ng803GhignaC.De ToledoM.BonomiS.ValaccaC.GalloS.ApicellaM.EperonI.TaziJ.BiamontiG.Pro-metastatic splicing of Ron proto-oncogene mRNA can be reversed: therapeutic potential of bifunctional oligonucleotides and indole derivatives2010744955032-s2.0-7795730225210.4161/rna.7.4.12744MittendorfK. F.DeatherageC. L.OhiM. D.SandersC. R.Tailoring of membrane proteins by alternative splicing of pre-mRNA201251285541555610.1021/bi3007065LucoR. F.AlloM.SchorI. E.KornblihttA. R.MisteliT.Epigenetics in alternative pre-mRNA splicing2011144116262-s2.0-7865096114910.1016/j.cell.2010.11.056PoulosM. G.BatraR.CharizanisK.SwansonM. S.Developments in RNA splicing and disease201131a0007782-s2.0-7996062739510.1101/cshperspect.a000778MillsJ. D.JanitzM.Alternative splicing of mRNA in the molecular pathology of neurodegenerative diseases201233510111024YapK.MakeyevE. V.Regulation of gene expression in mammalian nervous system through alternative pre-mRNA splicing coupled with RNA quality control mechanisms201310.1016/j.mcn.2013.01.003FuR. H.LiuS. P.HuangS. J.ChenH. J.ChenP. R.LinY. H.HoY. C.ChangW. L.TsaiC. H.ShyuW. C.LinS. Z.Aberrant alternative splicing events in Parkinson's disease201322465366110.3727/096368912X655154PearnJ.Classification of spinal muscular atrophies1980181749199222-s2.0-0018906764ZhouJ.ZhengX.ShenH.Targeting RNA-splicing for SMA treatment201233322322810.1007/s10059-012-0005-6ZhaoY.KoebisM.SuoS.OhnoS.IshiuraS.Regulation of the alternative splicing of sarcoplasmic reticulum Ca2+-ATPase1 (SERCA1) by phorbol 12-myristate 13-acetate (PMA) via a PKC pathway2012423221221710.1016/j.bbrc.2012.05.033CooperT. A.Alternative splicing regulation impacts heart development20051201122-s2.0-1184428151010.1016/j.cell.2004.12.030Lara-PezziE.DopazoA.ManzanaresM.Understanding cardiovascular disease: a journey through the genome (and what we found there)20125443444310.1242/dmm.009787BogdanovV. Y.Blood coagulation and alternative pre-mRNA splicing: an overview2006688598692-s2.0-3384536102610.2174/156652406779010821MedinaM. W.KraussR. M.Alternative splicing in the regulation of cholesterol homeostasis201324214715210.1097/MOL.0b013e32835cf284Endo-UmedaK.UnoS.FujimoriK.NaitoY.SaitoK.YamagishiK.JeongY.MiyachiH.TokiwaH.YamadaS.MakishimaM.Differential expression and function of alternative splicing variants of human liver X receptor alpha201281680081010.1124/mol.111.077206ManettiM.GuiducciS.Ibba-ManneschiL.Matucci-CerinicM.Impaired angiogenesis in systemic sclerosis: the emerging role of the antiangiogenic VEGF(165)b splice variant201121720421010.1016/j.tcm.2012.05.011XuX.YangD.DingJ. H.WangW.ChuP. H.DaltonN. D.WangH. Y.BerminghamJ. R.YeZ.LiuF.RosenfeldM. G.ManleyJ. L.RossJ.ChenJ.XiaoR. P.ChengH.FuX. D.ASF/SF2-regulated CaMKIIδ alternative splicing temporally reprograms excitation-contraction coupling in cardiac muscle2005120159722-s2.0-1994442765510.1016/j.cell.2004.11.036FedorovO.HuberK.EisenreichA.FilippakopoulosP.KingO.BullockA. N.SzklarczykD.JensenL. J.FabbroD.TrappeJ.RauchU.BracherF.KnappS.Specific CLK inhibitors from a novel chemotype for regulation of alternative splicing2011181677610.1016/j.chembiol.2010.11.009KongS. W.HuY. W.HoJ. W. K.IkedaS.PolsterS.JohnR.HallJ. L.BispingE.PieskeB.Dos RemediosC. G.PuW. T.Heart failure-associated changes in RNA splicing of sarcomere genes2010321381462-s2.0-7795367750310.1161/CIRCGENETICS.109.904698BurkhardtR.KennyE. E.LoweJ. K.BirkelandA.JosowitzR.NoelM.SalitJ.MallerJ. B.Pe'erI.DalyM. J.AltshulerD.StoffelM.FriedmanJ. M.BreslowJ. L.Common SNPs in HMGCR in micronesians and whites associated with LDL-cholesterol levels affect alternative splicing of exon1320082811207820842-s2.0-5544910522710.1161/ATVBAHA.108.172288ZhuH.TuckerH. M.GrearK. E.SimpsonJ. F.ManningA. K.CupplesL. A.EstusS.A common polymorphism decreases low-density lipoprotein receptor exon 12 splicing efficiency and associates with increased cholesterol20071614176517722-s2.0-3454779313110.1093/hmg/ddm124SchmidtR. J.ZhangY.ZhaoY.QianY. W.WangH.LinA.EhsaniM. E.YuX.WangG.SinghJ.SuE. W.LiS.KonradR. J.CaoG.A novel splicing variant of proprotein convertase subtilisin/kexin type 920082741831892-s2.0-4214919601410.1089/dna.2007.0667GilG.SmithJ. R.GoldsteinJ. L.BrownM. S.Optional exon in the 5′-untranslated region of 3-hydroxy-3-methylglutaryl coenzyme A synthase gene: conserved sequence and splicing pattern in humans and hamsters1987847186318662-s2.0-0023136487HoutenS. M.KosterJ.RomeijnG. J.FrenkelJ.Di RoccoM.CarusoU.LandrieuP.KelleyR. I.KuisW.Poll-TheB. T.GibsonK. M.WandersR. J. A.WaterhamH. R.Organization of the mevalonate kinase (MVK) gene and identification of novel mutations causing mevalonic aciduria and hyperimmunoglobulinaemia D and periodic fever syndrome2001942532592-s2.0-003506367610.1038/sj.ejhg.5200595KaidaD.Schneider-PoetschT.YoshidaM.Splicing in oncogenesis and tumor suppression201210391611161610.1111/j.1349-7006.2012.02356.xHagenR. M.LadomeryM. R.Role of splice variants in the metastatic progression of prostate cancer201240487087410.1042/BST20120026SampathJ.PelusL. M.Alternative splice variants of survivin as potential targets in cancer2007431741912-s2.0-3644894475910.2174/157016307782109652MiuraK.FujibuchiW.SasakiI.Alternative pre-mRNA splicing in digestive tract malignancy201110223093162-s2.0-7995208185210.1111/j.1349-7006.2010.01797.xOkumuraN.YoshidaH.KitagishiY.NishimuraY.MatsudaS.Alternative splicings on p53, BRCA1 and PTEN genes involved in breast cancer2011413339539910.1016/j.bbrc.2011.08.098TalieriM.DevetziM.ScorilasA.PappaE.TsapralisN.MissitzisI.ArdavanisA.Human kallikrein-related peptidase 12 (KLK12) splice variants expression in breast cancer and their clinical impact20123341075108410.1007/s13277-012-0347-xTammaroC.RaponiM.WilsonD. I.BaralleD.BRCA1 exon 11 alternative splicing, multiple functions and the association with cancer201240476877210.1042/BST20120140ZhongJ.CaoR. X.ZuX. Y.HongT.YangJ.LiuL.XiaoX. H.DingW. J.ZhaoQ.LiuJ. H.WenG. B.Identification and characterization of novel spliced variants of PRMT2 in breast carcinoma2012279231633510.1111/j.1742-4658.2011.08426.xAlbertH.SantosS.BattagliaE.BritoM.MonteiroC.BagrelD.Differential expression of CDC25 phosphatases splice variants in human breast cancer cells2011491017071714SebbanS.Golan-GerstlR.KarniR.VaksmanO.DavidsonB.ReichR.Alternatively spliced lysyl oxidase-like 4 isoforms have a pro-metastatic role in cancer201330110311710.1007/s10585-012-9514-0WangY.ChanD. W.LiuV. W. S.ChiuP. M.NganH. Y. S.Differential functions of growth factor receptor-bound protein 7 (GRB7) and its variant GRB7v in ovarian carcinogenesis2010169252925392-s2.0-7795175801710.1158/1078-0432.CCR-10-0018HaileS.SadarM. D.Androgen receptor and its splice variants in prostate cancer201168243971398110.1007/s00018-011-0766-7UsherP. A.SieuwertsA. M.BartelsA.LademannU.NielsenH. J.Holten-AndersenL.FoekensJ. A.BrünnerN.OffenbergH.Identification of alternatively spliced TIMP-1 mRNA in cancer cell lines and colon cancer tissue2007122052152-s2.0-3454757307410.1016/j.molonc.2007.05.002GotleyD. C.FawcettJ.WalshM. D.ReederJ. A.SimmonsD. L.AntalisT. M.Alternatively spliced variants of the cell adhesion molecule CD44 and tumour progression in colorectal cancer19967433423512-s2.0-0030055727PioR.MontuengaL. M.Alternative splicing in lung cancer2009466746782-s2.0-6784908712610.1097/JTO.0b013e3181a520dcMorettiD.Del BelloB.CosciE.BiagioliM.MiraccoC.MaellaroE.Novel variants of muscle calpain 3 identified in human melanoma cells: cisplatin-induced changes in vitro and differential expression in melanocytic lesions20093069609672-s2.0-6674917342710.1093/carcin/bgp098HanounN.BureauC.DiabT.GayetO.DusettiN.SelvesJ.VinelJ. P.BuscailL.CordelierP.TorrisaniJ.The SV2 variant of KLF6 is down-regulated in hepatocellular carcinoma and displays anti-proliferative and pro-apoptotic functions20105358808882-s2.0-7795732632110.1016/j.jhep.2010.04.038YiQ.TangL.Alternative spliced variants as biomarkers of colorectal cancer2011121096697410.2174/138920011798062355OmennG. S.YocumA. K.MenonR.Alternative splice variants, a new class of protein cancer biomarker candidates: findings in pancreatic cancer and breast cancer with systems biology implications20102842412512-s2.0-7795413174210.3233/DMA-2010-0702LeeY.GamazonE. R.RebmanE.LeeY.LeeS.DolanM. E.CoxN. J.LussierY. A.Variants affecting exon skipping contribute to complex traits2012810e1002998FengH.QinZ.ZhangX.Opportunities and methods for studying alternative splicing in cancer with RNA-Seq201210.1016/j.canlet.2012.11.010LiG.BahnJ. H.LeeJ. H.PengG.ChenZ.NelsonS. F.XiaoX.Identification of allele-specific alternative mRNA processing via transcriptome sequencing20124013, article e104XiL.FeberA.GuptaV.WuM.BergemannA. D.LandreneauR. J.LitleV. R.PennathurA.LuketichJ. D.GodfreyT. E.Whole genome exon arrays identify differential expression of alternatively spliced, cancer-related genes in lung cancer20083620653565472-s2.0-5664908377810.1093/nar/gkn697Ben-DovC.HartmannB.LundgrenJ.ValcárcelJ.Genome-wide analysis of alternative pre-mRNA splicing20082833122912332-s2.0-3834913253910.1074/jbc.R700033200GautschiO.RatschillerD.GuggerM.BetticherD. C.HeighwayJ.Cyclin D1 in non-small cell lung cancer: a key driver of malignant transformation20075511142-s2.0-3384595111010.1016/j.lungcan.2006.09.024LamolleG.MarinM.Alvarez-ValinF.Silent mutations in the gene encoding the p53 protein are preferentially located in conserved amino acid positions and splicing enhancers20066001-21021122-s2.0-3374748269210.1016/j.mrfmmm.2006.03.004NeklasonD. W.SolomonC. H.DaltonA. L.KuwadaS. K.BurtR. W.Intron 4 mutation in APC gene results in splice defect and attenuated FAP phenotype20043135402-s2.0-314269878410.1023/B:FAME.0000026824.85766.22RaponiM.KralovicovaJ.CopsonE.DivinaP.EcclesD.JohnsonP.BaralleD.VorechovskyI.Prediction of single-nucleotide substitutions that result in exon skipping: identification of a splicing silencer in BRCA1 exon 620113244364442-s2.0-7995275572010.1002/humu.21458LiuH. X.CartegniL.ZhangM. Q.KrainerA. R.A mechanism for exon skipping caused by nonsense or missense mutations in BRCA1 and other genes200127155582-s2.0-003515873010.1038/83762NarlaG.DiFeoA.ReevesH. L.SchaidD. J.HirshfeldJ.HodE.KatzA.IsaacsW. B.HebbringS.KomiyaA.McDonnellS. K.WileyK. E.JacobsenS. J.IsaacsS. D.WalshP. C.ZhengS. L.ChangB. L.FriedrichsenD. M.StanfordJ. L.OstranderE. A.ChinnaiyanA. M.RubinM. A.XuJ.ThibodeauS. N.FriedmanS. L.MartignettiJ. A.A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk2005654121312222-s2.0-1394425206510.1158/0008-5472.CAN-04-4249NarlaG.DifeoA.YaoS.BannoA.HodE.ReevesH. L.QiaoR. F.Camacho-VanegasO.LevineA.KirschenbaumA.ChanA. M.FriedmanS. L.MartignettiJ. A.Targeted inhibition of the KLF6 splice variant, KLF6 SV1, suppresses prostate cancer cell growth and spread20056513576157682-s2.0-2134447319610.1158/0008-5472.CAN-05-0217DiFeoA.FeldL.RodriguezE.WangC.BeerD. G.MartignettiJ. A.NarlaG.A functional role for KLF6-SV1 in lung adenocarcinoma prognosis and chemotherapy response20086849659702-s2.0-3944909099910.1158/0008-5472.CAN-07-2604YangJ. O.KimW. Y.BhakJ.ssSNPTarget: genome-wide splice-site single nucleotide polymorphism database20093012E1010E10202-s2.0-7174909210510.1002/humu.21128DouglasA. G.WoodM. J.RNA splicing: disease and therapy201110315116410.1093/bfgp/elr020SinghR. K.CooperT. A.Pre-mRNA splicing in disease and therapeutics201218847248210.1016/j.molmed.2012.06.006SpitaliP.Aartsma-RusA.Splice modulating therapies for human disease201214861085108810.1016/j.cell.2012.02.014MiuraK.FujibuchiW.UnnoM.Splice isoforms as therapeutic targets for colorectal cancer201233122311231910.1093/carcin/bgs347MaciejewskiJ. P.PadgettR. A.Defects in spliceosomal machinery: a new pathway of leukaemogenesis2012158216517310.1111/j.1365-2141.2012.09158.xHagiwaraM.Alternative splicing: a new drug target of the post-genome era200517541-23243312-s2.0-2914446373810.1016/j.bbapap.2005.09.010BlairC. A.ZiX.Potential molecular targeting of splice variants for cancer treatment20114911836839Van AlphenR. J.WiemerE. A. C.BurgerH.EskensF. A. L. M.The spliceosome as target for anticancer treatment200910022282322-s2.0-5874910529410.1038/sj.bjc.6604801BonnalS.VigevaniL.ValcarcelJ.The spliceosome as a target of novel antitumour drugs2012111184785910.1038/nrd3823BarrieE. S.SmithR. M.SanfordJ. C.SadeeW.mRNA transcript diversity creates new opportunities for pharmacological intervention201281562063010.1124/mol.111.076604ZhangM. L.LorsonC. L.AndrophyE. J.ZhouJ.An in vivo reporter system for measuring increased inclusion of exon 7 in SMN2 mRNA: potential therapy of SMA2001820153215382-s2.0-003515837110.1038/sj.gt.3301550AndreassiC.JareckiJ.ZhouJ.CoovertD. D.MonaniU. R.ChenX.WhitneyM.PollokB.ZhangM.AndrophyE.BurghesA. H. M.Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients20011024284128492-s2.0-0035891862LunnM. R.RootD. E.MartinoA. M.FlahertyS. P.KelleyB. P.CoovertD. D.BurghesA. H.Thi ManN.MorrisG. E.ZhouJ.AndrophyE. J.SumnerC. J.StockwellB. R.Indoprofen upregulates the survival motor neuron protein through a cyclooxygenase-independent mechanism20041111148914932-s2.0-884424001710.1016/j.chembiol.2004.08.024XuC.ChenX.GrzeschikS. M.GantaM.WangC. H.Hydroxyurea enhances SMN2 gene expression through nitric oxide release201112119242-s2.0-7995154940510.1007/s10048-010-0268-zWeihlC. C.ConnollyA. M.PestronkA.Valproate may improve strength and function in patients with type III/IV spinal muscle atrophy20066735005012-s2.0-3374708348810.1212/01.wnl.0000231139.26253.d0YuoC. Y.LinH. H.ChangY. S.YangW. K.ChangJ. G.5-(N-ethyl-N-isopropyl)-amiloride enhances SMN2 exon 7 inclusion and protein expression in spinal muscular atrophy cells200863126342-s2.0-3904912569910.1002/ana.21241AndreassiC.AngelozziC.TizianoF. D.VitaliT.De VincenziE.BoninsegnaA.VillanovaM.BertiniE.PiniA.NeriG.BraheC.Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy200412159652-s2.0-1074422998110.1038/sj.ejhg.5201102ZhangZ.KelemenO.Van SantenM. A.YeltonS. M.WendlandtA. E.SviripaV. M.BollenM.BeullensM.UrlaubH.LührmannR.WattD. S.StammS.Synthesis and characterization of pseudocantharidins, novel phosphatase modulators that promote the inclusion of exon 7 into the SMN (survival of motoneuron) pre-mRNA20112861210126101362-s2.0-7995316956810.1074/jbc.M110.183970HarahapI. S. K.SaitoT.SanL. P.SasakiN.GunadiNurputraD. K. P.YusoffS.YamamotoT.MorikawaS.NishimuraN.LeeM. J.TakeshimaY.MatsuoM.NishioH.Valproic acid increases SMN2 expression and modulates SF2/ASF and hnRNPA1 expression in SMA fibroblast cell lines20112-s2.0-7995569291510.1016/j.braindev.2011.04.010ZhengS.ChenY.DonahueC. P.WolfeM. S.VaraniG.Structural Basis for Stabilization of the Tau Pre-mRNA Splicing Regulatory Element by Novantrone (Mitoxantrone)20091655575662-s2.0-6574910506110.1016/j.chembiol.2009.03.009LewisJ. S.JordanV. C.Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance20055911-22472632-s2.0-2784451153810.1016/j.mrfmmm.2005.02.028LinS. L.YanL. Y.ZhangX. T.YuanJ.LiM.QiaoJ.WangZ. Y.SunQ. Y.ER-α36, a variant of ER-α, promotes tamoxifen agonist action in endometrial cancer cells via the MAPK/ERK and PI3K/Akt pathways2010522-s2.0-7774925282710.1371/journal.pone.0009013e9013ZaharievaE.ChipmanJ. K.SollerM.Alternative splicing interference by xenobiotics201229611210.1016/j.tox.2012.01.014KaidaD.MotoyoshiH.TashiroE.NojimaT.HagiwaraM.IshigamiK.WatanabeH.KitaharaT.YoshidaT.NakajimaH.TaniT.HorinouchiS.YoshidaM.Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA2007395765832-s2.0-3454809515710.1038/nchembio.2007.18KotakeY.SaganeK.OwaT.Mimori-KiyosueY.ShimizuH.UesugiM.IshihamaY.IwataM.MizuiY.Splicing factor SF3b as a target of the antitumor natural product pladienolide2007395705752-s2.0-3454810465910.1038/nchembio.2007.16FanL.LagisettiC.EdwardsC. C.WebbT. R.PotterP. M.Sudemycins, novel small molecule analogues of FR901464, induce alternative gene splicing2011665825892-s2.0-7996104973210.1021/cb100356kCorrioneroA.MiñanaB.ValcárcelJ.Reduced fidelity of branch point recognition and alternative splicing induced by the anti-tumor drug spliceostatin A20112554454592-s2.0-7995222080810.1101/gad.2014311FurumaiR.UchidaK.KomiY.YoneyamaM.IshigamiK.WatanabeH.KojimaS.YoshidaM.Spliceostatin A blocks angiogenesis by inhibiting global gene expression including VEGF201010111248324892-s2.0-7804942274610.1111/j.1349-7006.2010.01686.xNakajimaH.SatoB.FujitaT.TakaseS.TeranoH.OkuharaM.New antitumor substances, FR901463, FR901464 and FR901465: I. Taxonomy, fermentation, isolation, physico-chemical properties and biological activities19964912119612032-s2.0-0030461311AlbertB. J.McPhersonP. A.O'BrienK.CzaickiN. L.DeStefinoV.OsmanS.LiM.DayB. W.GrabowskiP. J.MooreM. J.VogtA.KoideK.Meayamycin inhibits pre-messenger RNA splicing and exhibits picomolar activity against multidrug-resistant cells200988230823182-s2.0-6884908404110.1158/1535-7163.MCT-09-0051WoolardJ.VousdenW.MossS. J.KrishnakumarA.GammonsM. V.NowakD. G.DixonN.MicklefieldJ.SpannhoffA.BedfordM. T.GregoryM. A.MartinC. J.LeadlayP. F.ZhangM. Q.HarperS. J.BatesD. O.WilkinsonB.Borrelidin modulates the alternative splicing of VEGF in favour of anti-angiogenic isoforms201120112273278ShamimU.HanifS.AlbanyanA.BeckF. W.BaoB.WangZ.BanerjeeS.SarkarF. H.MohammadR. M.HadiS. M.AzmiA. S.Resveratrol-induced apoptosis is enhanced in low pH environments associated with cancer201222741493150010.1002/jcp.22865JakubikovaJ.CerviD.OoiM.KimK.NaharS.KlippelS.CholujovaD.LeibaM.DaleyJ. F.DelmoreJ.NegriJ.BlottaS.McMillinD. W.HideshimaT.RichardsonP. G.SedlakJ.AndersonK. C.MitsiadesC. S.Anti-tumor activity and signaling events triggered by the isothiocyanates, sulforaphane and phenethyl isothiocyanate, in multiple myeloma20119681170117910.3324/haematol.2010.029363MarkusM. A.MarquesF. Z.MorrisB. J.Resveratrol, by modulating RNA processing factor levels, can influence the alternative splicing of pre-mRNAs2011612e28926MiuraK.FujibuchiW.UnnoM.Splice variants in apoptotic pathway2012343212217SchwerkC.Schulze-OsthoffK.Regulation of apoptosis by alternative pre-mRNA splicing20051911132-s2.0-2124443938010.1016/j.molcel.2005.05.026ShkretaL.FroehlichU.PaquetE. R.ToutantJ.ElelaS. A.ChabotB.Anticancer drugs affect the alternative splicing of Bcl-x and other human apoptotic genes200876139814092-s2.0-4984910221610.1158/1535-7163.MCT-08-0192LeeJ.ZhouJ.ZhengX.ChoS.MoonH.LohT. J.JoK.ShenH.Identification of a novel cis-element that regulates alternative splicing of Bcl-x pre-mRNA2012420246747210.1016/j.bbrc.2012.03.029RevilT.ToutantJ.ShkretaL.GarneauD.CloutierP.ChabotB.Protein kinase C-dependent control of Bcl-x alternative splicing20072724843184412-s2.0-3714901473710.1128/MCB.00565-07ShultzJ. C.GoeheR. W.WijesingheD. S.MurudkarC.HawkinsA. J.ShayJ. W.MinnaJ. D.ChalfantC. E.Alternative splicing of caspase 9 is modulated by the phosphoinositide 3-kinase/Akt pathway via phosphorylation of SRp30a20107022918591962-s2.0-7854923410210.1158/0008-5472.CAN-10-1545PuppinC.PassonN.FranzoniA.RussoD.DamanteG.Histone deacetylase inhibitors control the transcription and alternative splicing of prohibitin in thyroid tumor cells20112523933972-s2.0-7865137272610.3892/or.2010.1075WuS.LiC.HuangW.LiW.LiR. W.Alternative splicing regulated by butyrate in bovine epithelial cells201276e39182LeeC.WangQ.Bioinformatics analysis of alternative splicing20056123332-s2.0-1724437719510.1093/bib/6.1.23FloreaL. D.Bioinformatics of alternative splicing and its regulation20067155692-s2.0-3374877092110.1093/bib/bbk005KimN.LeeC.Bioinformatics detection of alternative splicing20084521791972-s2.0-4644912779510.1007/978-1-60327-159-2-9JiH.ZhouQ.WenF.XiaH.LuX.LiY.AsMamDB: an alternative splice database of mammals20012912602632-s2.0-0035175280HuangY. H.ChenY. T.LaiJ. J.YangS. T.YangU. C.PALS db: putative alternative splicing database20023011861902-s2.0-0036081021LeeC.AtanelovL.ModrekB.XingY.ASAP: the alternative splicing annotation project20033111011052-s2.0-003724671810.1093/nar/gkg029PospisilH.HerrmannA.BortfeldtR. H.ReichJ. G.EASED: Extended Alternatively Spliced EST Database200432D70D742-s2.0-0347899426HsuF. R.ChangH. Y.LinY. L.TsaiY. T.PengH. L.ChenY. T.ChengC. Y.ShihM. Y.LiuC. H.ChenC. F.AVATAR: a database for genome-wide alternative splicing event detection using large scale ESTs and mRNAs200511161810.6026/97320630001016ZhengC. L.KwonY. S.Hai-RiL. I.ZhangK.Coutinho-MansfieldG.YangC.Murlidharan NairT.GribskovM.Xiang-DongF. U.MAASE: an alternative splicing database designed for supporting splicing microarray applications20051112176717762-s2.0-2834443222410.1261/rna.2650905ZhangH.HuJ.RecceM.TianB.PolyA_DB: a database for mammalian mRNA polyadenylation200533D116D1202-s2.0-1344430277510.1093/nar/gki055Le TexierV.RiethovenJ. J.KumanduriV.GopalakrishnanC.LopezF.GautheretD.ThanarajT. A.AltTrans: transcript pattern variants annotated for both alternative splicing and alternative polyadenylation20067article 1692-s2.0-3364580850110.1186/1471-2105-7-169KostadinovR.MalhotraN.ViottiM.ShineR.D'AntonioL.BaggaP.GRSDB: a database of quadruplex forming G-rich sequences in alternatively processed mammalian pre-mRNA sequences200634D1191242-s2.0-33644877945HolsteD.HuoG.TungV.BurgeC. B.HOLLYWOOD: a comparative relational database of alternative splicing200634D56622-s2.0-33644877169StammS.RiethovenJ. J.Le TexierV.GopalakrishnanC.KumanduriV.TangY.Barbosa-MoraisN. L.ThanarajT. A.ASD: a bioinformatics resource on alternative splicing200634D46552-s2.0-33644878582RambaldiD.FeliceB.PrazV.BucherP.CittaroD.GuffantiA.Splicy: a web-based tool for the prediction of possible alternative splicing events from Affymetrix probeset data200781, article no. S172-s2.0-3424814004710.1186/1471-2105-8-S1-S17FoissacS.SammethM.ASTALAVISTA: dynamic and flexible analysis of alternative splicing events in custom gene datasets200735W2972992-s2.0-3454759950410.1093/nar/gkm311LacroixZ.LegendreC.RaschidL.SnyderB.BIPASS: BioInformatics Pipeline Alternative Splicing Services200735W2922962-s2.0-3454760247110.1093/nar/gkm344LeeY.LeeY.KimB.ShinY.NamS.KimP.KimN.ChungW. H.KimJ.LeeS.ECgene: an alternative splicing database update2007351D99D1032-s2.0-3384603970910.1093/nar/gkl992BhasiA.PandeyR. V.UtharasamyS. P.SenapathyP.EuSplice: a unified resource for the analysis of splice signals and alternative splicing in eukaryotic genes20072314181518232-s2.0-3454786958310.1093/bioinformatics/btm084RyanM. C.ZeebergB. R.CaplenN. J.ClelandJ. A.KahnA. B.LiuH.WeinsteinJ. N.SpliceCenter: a suite of web-based bioinformatic applications for evaluating the impact of alternative splicing on RT-PCR, RNAi, microarray, and peptide-based studies20089article 3132-s2.0-4854909180610.1186/1471-2105-9-313CastrignanòT.D'AntonioM.AnselmoA.CarrabinoD.D'Onorio de MeoA.D'ErchiaA. M.LicciulliF.MangiulliM.MignoneF.PavesiG.PicardiE.RivaA.RizziR.BonizzoniP.PesoleG.ASPicDB: a database resource for alternative splicing analysis20082410130013042-s2.0-4334908968710.1093/bioinformatics/btn113BechtelJ. M.RajeshP.IlikchyanI.DengY.MishraP. K.WangQ.WuX.AfoninK. A.GroseW. E.WangY.KhuderS.FedorovA.The Alternative Splicing Mutation Database: a hub for investigations of alternative splicing using mutational evidence20081article 32-s2.0-7794998890910.1186/1756-0500-1-3BirzeleF.KüffnerR.MeierF.OefingerF.PotthastC.ZimmerR.ProSAS: a database for analyzing alternative splicing in the context of protein structures2008361D63D682-s2.0-3854916743710.1093/nar/gkm793FlorisM.OrsiniM.ThanarajT. A.Splice-mediated variants of proteins (SpliVaP)—data and characterization of changes in signatures among protein isoforms due to alternative splicing20089article 4532-s2.0-5494913576410.1186/1471-2164-9-453BhasiA.PhilipP.SreedharanV. T.SenapathyP.AspAlt: a tool for inter-database, inter-genomic and user-specific comparative analysis of alternative transcription and alternative splicing in 46 eukaryotes200994148542-s2.0-6734920983710.1016/j.ygeno.2009.02.006KoscielnyG.TexierV. L.GopalakrishnanC.KumanduriV.RiethovenJ. J.NardoneF.StanleyE.FallsehrC.HofmannO.KullM.HarringtonE.BouéS.EyrasE.PlassM.LopezF.RitchieW.MoucadelV.AraT.PospisilH.HerrmannA.ReichJ. G.GuigóR.BorkP.DoeberitzM. V. K.ViloJ.HideW.ApweilerR.ThanarajT. A.GautheretD.ASTD: the Alternative Splicing and Transcript Diversity database20099332132202-s2.0-6004909358510.1016/j.ygeno.2008.11.003SinhaR.LenserT.JahnN.GausmannU.FriedelS.SzafranskiK.HuseK.RosenstielP.HampeJ.SchusterS.HillerM.BackofenR.PlatzerM.TassDB2: a comprehensive database of subtle alternative splicing events201011article 2162-s2.0-7795159470010.1186/1471-2105-11-216TakedaJ. I.SuzukiY.SakateR.SatoY.GojoboriT.ImanishiT.SuganoS.H-DBAS: Human-transcriptome database for alternative splicing: update 20102009381D86D902-s2.0-7554909015610.1093/nar/gkp984gkp984KrollJ. E.GalanteP. A.OharaD. T.NavarroF. C.Ohno-MachadoL.de SouzaS. J.SPLOOCE: a new portal for the analysis of human splicing variants201291113391343RodriguezJ. M.MaiettaP.EzkurdiaI.PietrelliA.WesselinkJ. J.LopezG.ValenciaA.TressM. L.APPRIS: annotation of principal and alternative splice isoforms20134111011710.1093/nar/gks959PivaF.GiuliettiM.BuriniA. B.PrincipatoG.SpliceAid 2: a database of human splicing factors expression data and RNA target motifs2012331818510.1002/humu.21609WingenderE.SchoepsT.DonitzJ.TFClass: an expandable hierarchical classification of human transcription factors20134116517010.1093/nar/gks1123